Paromomycin

DB01421

small molecule approved investigational

Deskripsi

An oligosaccharide antibiotic produced by various streptomyces. PubChem

Struktur Molekul 2D

Berat 615.6285
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Poorly absorbed after oral administration, with almost 100% of the drug recoverable in the stool.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Makanan

1 Data
  • 1. Take with food.

Interaksi Obat

868 Data
Succinylcholine The therapeutic efficacy of Succinylcholine can be increased when used in combination with Paromomycin.
Metocurine iodide The therapeutic efficacy of Metocurine iodide can be increased when used in combination with Paromomycin.
Gallamine triethiodide The therapeutic efficacy of Gallamine triethiodide can be increased when used in combination with Paromomycin.
Cisatracurium Paromomycin may increase the neuromuscular blocking activities of Cisatracurium.
Rocuronium The therapeutic efficacy of Rocuronium can be increased when used in combination with Paromomycin.
Atracurium besylate The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Paromomycin.
Doxacurium The therapeutic efficacy of Doxacurium can be increased when used in combination with Paromomycin.
Mivacurium The therapeutic efficacy of Mivacurium can be increased when used in combination with Paromomycin.
Decamethonium The therapeutic efficacy of Decamethonium can be increased when used in combination with Paromomycin.
Metocurine The therapeutic efficacy of Metocurine can be increased when used in combination with Paromomycin.
Pancuronium The therapeutic efficacy of Pancuronium can be increased when used in combination with Paromomycin.
Pipecuronium The therapeutic efficacy of Pipecuronium can be increased when used in combination with Paromomycin.
Vecuronium The therapeutic efficacy of Vecuronium can be increased when used in combination with Paromomycin.
Rapacuronium The therapeutic efficacy of Rapacuronium can be increased when used in combination with Paromomycin.
Pyrantel The therapeutic efficacy of Pyrantel can be increased when used in combination with Paromomycin.
Neosaxitoxin The therapeutic efficacy of Neosaxitoxin can be increased when used in combination with Paromomycin.
Atracurium The therapeutic efficacy of Atracurium can be increased when used in combination with Paromomycin.
Gallamine The therapeutic efficacy of Gallamine can be increased when used in combination with Paromomycin.
Alcuronium The therapeutic efficacy of Alcuronium can be increased when used in combination with Paromomycin.
Tubocurarine The therapeutic efficacy of Tubocurarine can be increased when used in combination with Paromomycin.
Carboplatin The risk or severity of ototoxicity and nephrotoxicity can be increased when Paromomycin is combined with Carboplatin.
Foscarnet The risk or severity of nephrotoxicity can be increased when Paromomycin is combined with Foscarnet.
Mannitol The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Paromomycin.
Tenofovir disoproxil Paromomycin may increase the nephrotoxic activities of Tenofovir disoproxil.
Tenofovir alafenamide Paromomycin may increase the nephrotoxic activities of Tenofovir alafenamide.
Tenofovir Paromomycin may increase the nephrotoxic activities of Tenofovir.
Picosulfuric acid The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Paromomycin.
Zoledronic acid The risk or severity of nephrotoxicity and hypocalcemia can be increased when Paromomycin is combined with Zoledronic acid.
Alendronic acid The risk or severity of nephrotoxicity and hypocalcemia can be increased when Paromomycin is combined with Alendronic acid.
Ibandronate The risk or severity of nephrotoxicity and hypocalcemia can be increased when Paromomycin is combined with Ibandronate.
Clodronic acid The risk or severity of nephrotoxicity and hypocalcemia can be increased when Paromomycin is combined with Clodronic acid.
Risedronic acid The risk or severity of nephrotoxicity and hypocalcemia can be increased when Paromomycin is combined with Risedronic acid.
Etidronic acid The risk or severity of nephrotoxicity and hypocalcemia can be increased when Paromomycin is combined with Etidronic acid.
Incadronic acid The risk or severity of nephrotoxicity and hypocalcemia can be increased when Paromomycin is combined with Incadronic acid.
Pamidronic acid The risk or severity of nephrotoxicity and hypocalcemia can be increased when Paromomycin is combined with Pamidronic acid.
Tiludronic acid The risk or severity of nephrotoxicity and hypocalcemia can be increased when Paromomycin is combined with Tiludronic acid.
Cyclosporine The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Paromomycin.
Icosapent The risk or severity of nephrotoxicity can be increased when Icosapent is combined with Paromomycin.
Cefotiam The risk or severity of nephrotoxicity can be increased when Cefotiam is combined with Paromomycin.
Mesalazine The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Paromomycin.
Cefmenoxime The risk or severity of nephrotoxicity can be increased when Cefmenoxime is combined with Paromomycin.
Cefmetazole The risk or severity of nephrotoxicity can be increased when Cefmetazole is combined with Paromomycin.
Indomethacin The risk or severity of nephrotoxicity can be increased when Indomethacin is combined with Paromomycin.
Cidofovir The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Paromomycin.
Triamterene The risk or severity of nephrotoxicity can be increased when Triamterene is combined with Paromomycin.
Cefpiramide The risk or severity of nephrotoxicity can be increased when Cefpiramide is combined with Paromomycin.
Ceftazidime The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Paromomycin.
Loracarbef The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Paromomycin.
Framycetin The risk or severity of nephrotoxicity can be increased when Framycetin is combined with Paromomycin.
Cefalotin The risk or severity of nephrotoxicity can be increased when Cefalotin is combined with Paromomycin.
Nabumetone The risk or severity of nephrotoxicity can be increased when Nabumetone is combined with Paromomycin.
Ketorolac The risk or severity of nephrotoxicity can be increased when Ketorolac is combined with Paromomycin.
Tenoxicam The risk or severity of nephrotoxicity can be increased when Tenoxicam is combined with Paromomycin.
Celecoxib The risk or severity of nephrotoxicity can be increased when Celecoxib is combined with Paromomycin.
Cefotaxime The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Paromomycin.
Tolmetin The risk or severity of nephrotoxicity can be increased when Tolmetin is combined with Paromomycin.
Rofecoxib The risk or severity of nephrotoxicity can be increased when Rofecoxib is combined with Paromomycin.
Piroxicam The risk or severity of nephrotoxicity can be increased when Piroxicam is combined with Paromomycin.
Methotrexate The risk or severity of nephrotoxicity can be increased when Methotrexate is combined with Paromomycin.
Cephalexin The risk or severity of nephrotoxicity can be increased when Cephalexin is combined with Paromomycin.
Fenoprofen The risk or severity of nephrotoxicity can be increased when Fenoprofen is combined with Paromomycin.
Valaciclovir The risk or severity of nephrotoxicity can be increased when Valaciclovir is combined with Paromomycin.
Valdecoxib The risk or severity of nephrotoxicity can be increased when Valdecoxib is combined with Paromomycin.
Diclofenac The risk or severity of nephrotoxicity can be increased when Diclofenac is combined with Paromomycin.
Sulindac The risk or severity of nephrotoxicity can be increased when Sulindac is combined with Paromomycin.
Bacitracin The risk or severity of nephrotoxicity can be increased when Bacitracin is combined with Paromomycin.
Amphotericin B The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Paromomycin.
Cephaloglycin The risk or severity of nephrotoxicity can be increased when Cephaloglycin is combined with Paromomycin.
Flurbiprofen The risk or severity of nephrotoxicity can be increased when Flurbiprofen is combined with Paromomycin.
Adefovir dipivoxil The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Paromomycin.
Pentamidine The risk or severity of nephrotoxicity can be increased when Pentamidine is combined with Paromomycin.
Etodolac The risk or severity of nephrotoxicity can be increased when Etodolac is combined with Paromomycin.
Mefenamic acid The risk or severity of nephrotoxicity can be increased when Mefenamic acid is combined with Paromomycin.
Acyclovir The risk or severity of nephrotoxicity can be increased when Acyclovir is combined with Paromomycin.
Naproxen The risk or severity of nephrotoxicity can be increased when Naproxen is combined with Paromomycin.
Sulfasalazine The risk or severity of nephrotoxicity can be increased when Sulfasalazine is combined with Paromomycin.
Phenylbutazone The risk or severity of nephrotoxicity can be increased when Phenylbutazone is combined with Paromomycin.
Meloxicam The risk or severity of methemoglobinemia can be increased when Paromomycin is combined with Meloxicam.
Carprofen The risk or severity of nephrotoxicity can be increased when Carprofen is combined with Paromomycin.
Cefaclor The risk or severity of nephrotoxicity can be increased when Cefaclor is combined with Paromomycin.
Diflunisal The risk or severity of nephrotoxicity can be increased when Diflunisal is combined with Paromomycin.
Tacrolimus The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Paromomycin.
Ceforanide The risk or severity of nephrotoxicity can be increased when Ceforanide is combined with Paromomycin.
Salicylic acid The risk or severity of nephrotoxicity can be increased when Salicylic acid is combined with Paromomycin.
Meclofenamic acid The risk or severity of nephrotoxicity can be increased when Meclofenamic acid is combined with Paromomycin.
Acetylsalicylic acid The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Paromomycin.
Oxaprozin The risk or severity of nephrotoxicity can be increased when Oxaprozin is combined with Paromomycin.
Hydrochlorothiazide The risk or severity of nephrotoxicity can be increased when Hydrochlorothiazide is combined with Paromomycin.
Ketoprofen The risk or severity of nephrotoxicity can be increased when Ketoprofen is combined with Paromomycin.
Balsalazide The risk or severity of nephrotoxicity can be increased when Balsalazide is combined with Paromomycin.
Ibuprofen The risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Paromomycin.
Cefditoren The risk or severity of nephrotoxicity can be increased when Cefditoren is combined with Paromomycin.
Atazanavir The risk or severity of nephrotoxicity can be increased when Atazanavir is combined with Paromomycin.
Colistimethate The risk or severity of nephrotoxicity can be increased when Colistimethate is combined with Paromomycin.
Cefuroxime The risk or severity of nephrotoxicity can be increased when Cefuroxime is combined with Paromomycin.
Cefapirin The risk or severity of nephrotoxicity can be increased when Cefapirin is combined with Paromomycin.
Cefadroxil The risk or severity of nephrotoxicity can be increased when Cefadroxil is combined with Paromomycin.
Cefprozil The risk or severity of nephrotoxicity can be increased when Cefprozil is combined with Paromomycin.
Ceftriaxone The risk or severity of nephrotoxicity can be increased when Ceftriaxone is combined with Paromomycin.
Olsalazine The risk or severity of nephrotoxicity can be increased when Paromomycin is combined with Olsalazine.

Target Protein

30S ribosomal protein S10 rpsJ
16S ribosomal RNA
Small ribosomal subunit protein uS2 RPSA
Ribosomal protein uL16-like RPL10L

Referensi & Sumber

Synthesis reference: Federico Arcamone, Giuseppe Cassinelli, "Paromomycin derivatives and process for the preparation thereof." U.S. Patent US4021601, issued October, 1967.
Artikel (PubMed)
  • PMID: 11587639
    Vicens Q, Westhof E: Crystal structure of paromomycin docked into the eubacterial ribosomal decoding A site. Structure. 2001 Aug;9(8):647-58.

Contoh Produk & Brand

Produk: 11 • International brands: 0
Produk
  • Humatin
    Capsule • 250 mg/1 • Oral • US • Generic • Approved
  • Humatin
    Capsule • 250 mg/1 • Oral • US
  • Humatin
    Capsule • 250 mg/1 • Oral • US • Generic • Approved
  • Humatin
    Capsule • 250 mg/1 • Oral • US • Generic • Approved
  • Humatin
    Capsule • 250 mg • Oral • Canada • Approved
  • Paromomycin Sulfate
    Capsule, gelatin coated • 250 mg/1 • Oral • US • Generic • Approved
  • Paromomycin Sulfate
    Capsule • 250 mg/1 • Oral • US • Generic • Approved
  • Paromomycin Sulfate
    Capsule • 250 mg/1 • Oral • US • Generic • Approved
Menampilkan 8 dari 11 produk.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul